Optum Rx
Revenue is flat year over year and adjusted scripts fell to 393 million in Q3 2026 from 414 million, while operating earnings rose.
The numbers
What it is
Pharmacy benefit manager for employers and health plans, running pharmacy networks, claims processing and mail-order dispensing. PBM pricing and rebate practices are a recurring focus of policy debate.
Why it matters to the stock. Optum Rx is the largest Optum segment by revenue. Prescription volume and PBM pricing rules drive its margin and the policy risk around the whole company.
News
UnitedHealth Q3 2026 adjusted EPS $4.69 vs $2.92 a year ago; 2026 adjusted EPS floor raised to $20.50
UnitedHealth reported third-quarter 2026 revenue of $112.7 billion, slightly below $113.2 billion a year earlier, and adjusted EPS of $4.69 against $2.92.
UnitedHealth Q2 2026 adjusted EPS $6.38 vs $4.08; full-year adjusted EPS guidance raised to $19.50-$20.00
UnitedHealth reported second-quarter 2026 revenue of $112.0 billion and adjusted EPS of $6.38, up from $4.08 a year earlier.
FTC pulls its OptumRx insulin pricing case to review a final settlement
The Federal Trade Commission withdrew its in-house case against OptumRx from adjudication so it could review a final settlement, Law360 reported on June 15, 2026.
Optum Rx launches fee-based pharmacy care model that drops list-price and volume pricing
Optum Rx introduced a fee-based pharmacy care model on May 11, 2026, offered to every Optum Rx PBM client.
UnitedHealth enters arrangement to repurchase at least $2 billion of stock
UnitedHealth entered into an arrangement to buy back at least $2 billion of its common stock, expected to be completed by the end of the second quarter of 2026.